Crossmark

Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients

Crossref DOI link: https://doi.org/10.1007/s12094-017-1808-x

Published Online: 2017-12-08

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Godoy-Ortiz, A. https://orcid.org/0000-0002-5503-6946
Plata, Y.

Alcaide, J.

Galeote, A.

Pajares, B.

Saez, E.

Alba, E.

Sánchez-Muñoz, A.
License Information

License valid from 2017-12-08